Targeting the HGF/Met signaling pathway in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 6, 2012, Pages 553-572

  Cecchi, Fabiola ^a   Rabe, Danie C ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

hepatocyte growth factor; MET

Indexed keywords

AMUVATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FICLATUZUMAB; FLUOROURACIL; FOLINIC ACID; FORETINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; METMAB; MITOXANTRONE; OMEPRAZOLE; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PREDNISONE; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOCARCINOMA; ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME 7; COLORECTAL CANCER; DISEASE CONTROL; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GLIOBLASTOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; UTERINE TUBE CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84861304952     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.680957     Document Type: Review

References (147)

1. Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007;26:1276-85 (Pubitemid 46328462)
2. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 2011;26:188-202
3. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993;123:223-35 (Pubitemid 23284877)
4. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol 2009;4:444-7
5. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78 (Pubitemid 21905304)
6. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-25 (Pubitemid 36791889)
7. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42 (Pubitemid 17071053)
8. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 1991;251:802-4 (Pubitemid 21926175)
9. Corso S, Comoglio PM, Giordano S. Cancer therapy: Can the challenge be MET? Trends Mol Med 2005;11:284-92 (Pubitemid 40804792)
10. Rosario M, Birchmeier W. How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003;13:328-35 (Pubitemid 36638800)
11. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-17 (Pubitemid 36119916)
12. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25 (Pubitemid 37493640)
13. Liu Y. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-17 (Pubitemid 43323069)
14. Borowiak M, Garratt AN, Wustefeld T, et al. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 2004;101:10608-13 (Pubitemid 38955789)
15. Huh CG, Factor VM, Sanchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004;101:4477-82 (Pubitemid 38437436)
16. Morishita R, Aoki M, Hashiya N, et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004;4:199-206 (Pubitemid 38842622)
17. Matsumoto K, Nakamura T. Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023-38 (Pubitemid 32467594)
18. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3 (Pubitemid 24116158)
19. Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59 (Pubitemid 34436961)
20. Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res 2004;119:121-38
21. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 2003;100:12039-44 (Pubitemid 37271511)
22. Niemann HH, Jager V, Butler PJ, et al. Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell 2007;130:235-46 (Pubitemid 47081132)
23. Antipenko A, Himanen JP, van Leyen K, et al. Structure of the semaphorin-3A receptor binding module. Neuron 2003;39:589-98 (Pubitemid 36993577)
24. Love CA, Harlos K, Mavaddat N, et al. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat Struct Biol 2003;10:843-8 (Pubitemid 37187657)
25. Kozlov G, Perreault A, Schrag JD, et al. Insights into function of PSI domains from structure of the Met receptor PSI domain. Biochem Biophys Res Commun 2004;321:234-40 (Pubitemid 39055629)
26. Basilico C, Arnesano A, Galluzzo M, et al. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 2008;283:21267-77
27. Crepaldi T, Pollack AL, Prat M, et al. Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol 1994;125:313-20 (Pubitemid 24135945)
28. Villa-Moruzzi E, Puntoni F, Bardelli A, et al. Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. Biochem J 1998;336:235-9 (Pubitemid 28532582)
29. Comoglio PM, Boccaccio C. Scatter factors and invasive growth. Semin Cancer Biol 2001;11:153-65 (Pubitemid 32423290)
30. Giordano S, Bardelli A, Zhen Z, et al. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc Natl Acad Sci USA 1997;94:13868-72 (Pubitemid 28009676)
31. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol 2003;13:122-30
32. Zang T, Zhuang L, Zhang Z, et al. Expression of beta-catenin in renal cell carcinoma. Chin Med J (Engl) 2001;114:152-4 (Pubitemid 33611111)
33. Available from: Http://www.vai.org/met/2012
34. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci 2006;103:2316-21 (Pubitemid 43271667)
35. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-82 (Pubitemid 40038747)
36. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702
37. Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004;4:855-68 (Pubitemid 39585731)
38. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 2007;7:77-84 (Pubitemid 46322280)
39. Bardelli A, Longati P, Gramaglia D, et al. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci USA 1998;95:14379-83 (Pubitemid 28549375)
40. Giordano S, Maffe A, Williams TA, et al. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J 2000;14:399-406 (Pubitemid 30086077)
41. Michieli P, Basilico C, Pennacchietti S, et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999;18:5221-31 (Pubitemid 29460658)
42. Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle 2005;4:518-20 (Pubitemid 41359769)
43. Joffre C, Barrow R, Menard L, et al. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011;13:827-37
44. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-9 (Pubitemid 43166034)
45. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81 (Pubitemid 37255174)
46. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and Its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88 (Pubitemid 40270177)
47. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50 (Pubitemid 29192711)
48. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000;19:4947-53
49. Tyner JW, Fletcher LB, Wang EQ, et al. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010;70:6233-7
50. Corso S, Migliore C, Ghiso E, et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008;27:684-93 (Pubitemid 351158907)
51. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61 (Pubitemid 38340304)
52. Stahl SJ, Wingfield PT, Kaufman JD, et al. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J 1997;326:763-72 (Pubitemid 27438050)
53. Yu Y, Merlino G. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res 2002;62:2951-6 (Pubitemid 34525784)
54. Toyoda M, Takayama H, Horiguchi N, et al. Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett 2001;509:95-100 (Pubitemid 33153088)
55. Otsuka T, Horiguchi N, Kanda D, et al. Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice. World J Gastroenterol 2005;11:7444-9 (Pubitemid 43126024)
56. Montesano R, Soriano JV, Malinda KM, et al. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 1998;9:355-65 (Pubitemid 28345875)
57. Kishi Y, Kuba K, Nakamura T, et al. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci 2009;100:1351-8
58. Suzuki Y, Sakai K, Ueki J, et al. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 2010;127:1948-57
59. Naka D, Ishii T, Yoshiyama Y, et al. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem 1992;267:20114-19
60. Lokker NA, Mark MR, Luis EA, et al. Structure-function analysis of hepatocyte growth factor: Identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992;11:2503-10
61. Hartmann G, Naldini L, Weidner KM, et al. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci USA 1992;89:11574-8
62. Gak E, Taylor WG, Chan AM, Rubin JS. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett 1992;311:17-21
63. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004;6:75-84 (Pubitemid 38903163)
64. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73 (Pubitemid 38903162)
65. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006;103:5090-5
66. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met-dependent human tumors. Cancer Res 2006;66:1721-9 (Pubitemid 43259957)
67. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-8 (Pubitemid 43342521)
68. Meetze AK, Boudrow A, Venkataraman S, et al. Preclinical efficacy and pharmacodynamics of SCH 900105 (AV-299) and anti-HGF antibody in an intracranial glioblastoma. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
69. Ramanathan RK, Payumo FC, Papadopoulos PK, et al. A Phase 1 first-in-human study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid cancer. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
70. Okamoto W, Okamoto I, Tanaka K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010;9:2785-92
71. Meetze AK, Boudrow A, Connoly K, et al. Anti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody in non-small cell lung cancer models. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
72. Kitahara O, Nishizawa S, Ito Y, et al. In vitro profiles of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, and the antitumor activity against U-87MG GBM with anti-angiogenic activity. American Association for Cancer Research (AACR) Annual Meeting; Denver, CO; 2009
73. Hori A, Kitahara O, Ito Y, et al. Monotherapeutic and combination antitumor activities of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer. American Association for Cancer Research (AACR) Annual Meeting; Denver, CO; 2009
74. Jones SF, Cohen RB, Bendell JC, et al. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2010
75. Available from: Http://investor. millennium.com/phoenix.zhtml? c=80159&p=irolnewsArticle&ID=1435576&highlight=2012
76. Rosen PJ, Sweeney CJ Park DJ, Beaupre DM, et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010;16:2677-87
77. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncol 2011;13:437-46
78. Ivenson T, Donehower RC, Davidenko I, et al. Safety and efficacy of epirubicin, cisplastin and capecitabine (ECX) plus rilutumab(R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma. European Multidisciplinary Cancer Congress; Stockholm; 2011
79. Eng C, Van Cutsem E, Nowara E, et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2011
80. Tan K, Park K, Lim M, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2011
81. Corvaia N, Gonzalez A, Boute N, et al. First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: I) in vitro mechanism of action. American Association for Cancer Research (AACR) Annual Meeting; Denver, CO; 2009
82. Gordon MS, Mendelson DS, Sweeney C, et al. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors. American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2007
83. Martens T, Schmidt NO, Eckerich C, et al. Inhibition of intracerebral glioblastoma growth by treatment with a novel one-armed anti-Met antibody. World Federation of Neuro-Oncology; Edinburgh, United Kingdom; 2005
84. Spigel DR, Ervin TJ, Ramlau RM, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2011
85. Available from: Http://www.ascopost. com/articles/october-15-2011- supplement/research-increasingly-pointsto-the-role-of-molecular-diversity- inmetastatic-lung-cancer/ 2012
86. Spigel DR, Waterhouse D, Shipley D, et al. Phase II trial of modified FOLFOX6, bevacizumab, and cetuximab in first-line metastatic colorectal cancer treatment. American Society of Clinical Oncology (ASCO), Gastrointestinal Cancers Symposium; San Francisco, CA; 2009
87. Merchant M, Marik J, Peng J, et al. Proof of concept of immuno-PET molecular imaging of met using 76Brand 89Zr-labeled MetMAb. American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2011
88. Perk LR, Stigter-van Walsum M, Visser GW, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008;10:1857-67
89. Bellon SF, Kaplan-Lefko P, Yang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-83
90. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9 (Pubitemid 37139865)
91. Ma PC, Wu C, Tang Z, et al. In vivo PET imaging of MET receptor in human cancer using [11C]SU11274. American Association for Cancer Research (AACR) Annual Meeting; Washington, DC; 2010
92. Wu C, Tang Z, Fan W, et al. In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem 2010;53:139-46
93. Viswanadha S, Muthuppalaniappan M, Varanasi KVS, et al. Pharmacological and pharmacokinetic characterization of RP1040, a novel and potent c-Met tyrosine kinase inhibitor. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
94. Burbridge MF, Bossard C, Saunier C, et al. Preclinical molecular stratification of human tumors sensitive or resistant to S 49076, a novel MET/ FGFR/ AXL kinase inhibitor. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; San Francisco, CA; 2011
95. Burbridge MF, Bossard C, Saunier C, et al. S 49076, a novel, potent, MET/FGFR/ AXL kinase inhibitor with wide antitumor activity. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; San Francisco, CA; 2011
96. Donehower RC, Sacrdina M, Hill M, et al. A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2011
97. Yang WJ, Credille K, Gao H, et al. LY2801653, an orally available small molecule inhibitor of c-Met, demonstrated broad antitumor efficacy in patients derived xenograft models. American Association for Cancer Research (AACR) Annual Meeting; Washington, DC; 2010
98. Bladt F, Blaukat A, Dorsch D, et al. Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the c-Met kinase in Phase I clinical trials. American Association for Cancer Research (AACR) Annual Meeting; Washington, DC; 2010
99. Bladt F, Blaukat A, Dorsch D, et al. Identification and preclinical characterization of EMD1204831 - a selective c-Met kinase inhibitor in clinical phase I. American Association for Cancer Research (AACR) Annual Meeting; Orlando, FL; 2011
100. Diamond S, Boer J, Maduskuie TP Jr, et al. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 2010;38:1277-85
101. Available from: Http://www.mskcc.org/mskcc/html/66036.cfm 2012
102. Nakagawa T, Tohyama O, Yamaguchi A, et al. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010;101:210-15
103. Qi W, Cooke LS, Stejskal A, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 2009;9:142
104. Welsh JW, Mahadevan D, Ellsworth R, et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009;4:69
105. Sankhala KK, Tolcher AW Mita MM, Gordon MS, et al. Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2011
106. Available from: Http://clinicaltrials.gov/ct2/show/NCT01357395 2012
107. Schroeder GM, An Y, Cai ZW, et al. Discovery of N-(4-(2-amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluor ophenyl)-2-oxo-1,2- dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-4
108. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010;9:1554-61
109. Hong D, LoRusso P, Kurzroc R, et al. Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265-102). American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2009
110. Besterman JM, Fournel M, Dupont I, et al. Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2010
111. Pan BS, Chan GK, Chenard M, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 2010;70:1524-33
112. Camacho LH, Moulder SL, LoRusso PM, et al. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2008
113. Eder JP, Health E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2007
114. Jhawer M, Kindler HL, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2009
115. Ross RW, Stein M, Sarantopoulos J, et al. A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2007
116. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2008
117. Liu L, Shi H, Liu Y, et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther 2011;10:518-30
118. Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011;286:20666-76
119. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-53
120. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17 (Pubitemid 46815090)
121. Matteucci E, Bendinelli P, Desiderio MA. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 2009;30:937-45
122. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2010
123. Available from: Http://www. daiichisankyo.com/news/detail/003880. html 2012
124. Salgia R, Honk DS, Camacho LH, et al. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2007
125. Salgia R, Sherman S, Hong DS, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2008
126. Vergote I, Sella A, Bedell C, et al. Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Berlin, Germany; 2010
127. Nuchushtan H, Edelman G, Jerusalem G, et al. Phase 2 results of XL184 in a cohort of patients (pts) with advanced melanoma. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Berlin, Germany; 2010
128. Yasenchak C, Nackaerts K, Awada S, et al. Phase 2 results of Cabozantinib (XL184) in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC). AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Berlin, Germany; 2010
129. Van Cutsem E, Su WC, Davis J, et al. Phase 2 study of XL184 in a cohort of patients (pts) with hepatocellular carcinoma (HCC). AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Berlin, Germany; 2010
130. Available from: Http://chicago2011.asco. org/ASCODailyNews/Abstract4516. aspx
131. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2011
132. Smith DC, Smith MR, Small EJ, et al. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. American Society of Clinical Oncology (ASCO), Genitourinary Cancers Symposium; Orlando, FL; 2011
133. Basch E, Bennett AV, Scher HI. Cabozantinib (XL184) reduces pain symptoms in patients (pts) with castration resistant prostate cancer (CRPC) and bone metastases: Results from a phase 2 non-randomized expansion cohort. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; San Francisco, CA; 2011
134. Lee RJB, Dror Michaelson M, Saylor P, et al. Efficacy and Tolerability of Cabozantinib at lower dose: A dose finding study in men with castration-resistant prostate cancer and bone metastases. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Berlin, Germany; 2011
135. Available from: Http://www.cancer.gov/cancertopics/druginfo/fda- crizotinib
136. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-6
137. Peach ML, Tan N, Choyke S, et al. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J Med Chem 2009;52:943-51
138. Muller T, DePrimo S, McGrath G, et al. Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, and oral, potent inhibitor of MET, VEGFR2, and RET. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
139. Pena C, Shan M, Bukowski RM, et al. Plasma biomarkers predicting outcome in patients with advanced RCC: Results from the sorafenib phase II TARGET trial. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
140. Heymach JV, Fritsche HA, Gornet TG, et al. Lower baseline levels of plasm hepatocyte growth factor, IL-6, IL08 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
141. Tanimoto S, Fukumori T, El-Moula G, et al. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: Comparison with serum vascular endothelial growth factor. J Med Invest 2008. 55106-55111
142. Cecchi F, Liu Y, Gagnon RC, et al. ShedMET (sMet), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients. AACR-NCI-EORTC International Conference Molecular Target and Cancer Therapeutics; Boston, MA; 2009
143. Kollmannsberger CK, Hurwitz H, Vlahovic G, et al. Phase I study of daily administration of MGCD265 to patients with advanced malignancies (study 265-101). American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL; 2009
144. DePrimo S, Wu B, Huang S, et al. Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM). American Society of Clinical Oncology (ASCO), Annual Meeting; Chicago, IL; 2009
145. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87
146. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43 (Pubitemid 46799492)
147. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26